Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:26 AM
Ignite Modification Date: 2025-12-25 @ 11:37 PM
NCT ID: NCT00406393
Description: Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event.
Frequency Threshold: 5
Time Frame: 2-years post transplant
Study: NCT00406393
Study Brief: Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Tacrolimus/Sirolimus Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis. None None 9 149 0 149 View
Tacrolimus/Methotrexate Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis. None None 12 152 0 152 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Osteonecrosis NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.0) View
VIIth nerve paralysis NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (12.0) View
Neuropathy peripheral NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (12.0) View
Mental status changes NON_SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (12.0) View
Death NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (12.0) View
Embolism NON_SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (12.0) View
Aphasia NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (12.0) View
Thoracotomy NON_SYSTEMATIC_ASSESSMENT Surgical and medical procedures MedDRA (12.0) View
Retinal tear NON_SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.0) View
Chest pain NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (12.0) View
Staphylococcal infection NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (12.0) View
Cerebrovascular accident NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (12.0) View
Pericardial effusion NON_SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (12.0) View
Subdural haematoma NON_SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (12.0) View
Septic shock NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (12.0) View
Glaucoma NON_SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (12.0) View
Pneumothorax NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (12.0) View
Myositis NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (12.0) View
Cholecystitis NON_SYSTEMATIC_ASSESSMENT Hepatobiliary disorders MedDRA (12.0) View
Supraventricular tachycardia NON_SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (12.0) View
Pneumonitis NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (12.0) View
Other Events(If Any):